Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Rinvoq is an oral medication that falls into the drug classification ... the company notes that Rinvoq relieves symptoms of moderate to severe eczema (atopic dermatitis), rheumatoid arthritis ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals 12 years and older with eczema ... with the drug, and the warnings ...

Hydroxyzine oral tablet is a generic prescription drug used for anxiety or itching ... itchiness due to an allergic condition, such as eczema. The typical dosage is 25 mg taken three or four ...

measured using the Hand Eczema Severity Index (HECSI) scale. More severe cases of CHE are also sometimes treated with oral retinoid drug alitretinoin, but that drug is associated with side effects ...

Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company ...

Novartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million ... the company said it had discontinued development of the oral H4 receptor antagonist.

The clinical trial is for a new drug for people with moderate to severe eczema, the NHS trust says The first UK patient has been recruited to take part in a clinical trial for a new drug for ...

In particular, she cited ongoing phase 3 trials with the topical pan-JAK inhibitor delgocitinib for chronic hand eczema. The FDA accepted the new drug application for delgocitinib for the ...

Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.